Effects of 20 mg rosuvastatin on VLDL1-, VLDL2-, IDL- and LDL-ApoB kinetics in type 2 diabetes (Q46554828)

23 December 2017

title

Effects of 20 mg rosuvastatin on VLDL1-, VLDL2-, IDL- and LDL-ApoB kinetics in type 2 diabetes (English)

1 reference

23 December 2017

1 reference

B Vergès

1

1 reference

23 December 2017

E Florentin

2

1 reference

23 December 2017

S Baillot-Rudoni

3

1 reference

23 December 2017

S Monier

4

1 reference

23 December 2017

J M Petit

5

1 reference

23 December 2017

D Rageot

6

1 reference

23 December 2017

P Gambert

7

1 reference

23 December 2017

L Duvillard

8

1 reference

23 December 2017

publication date

5 June 2008

1 reference

23 December 2017

published in

Diabetologia

1 reference

23 December 2017

volume

51

1 reference

23 December 2017

issue

8

1 reference

23 December 2017

page(s)

1382-1390

1 reference

23 December 2017

https://scigraph.springernature.com/pub.10.1007/s00125-008-1046-4

exact match

0 references

cites work

Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23)

1 reference

https://api.crossref.org/works/10.1007%2FS00125-008-1046-4

Development of compartmental models in stable-isotope experiments: application to lipid metabolism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-008-1046-4

Pitavastatin enhanced lipoprotein lipase expression in 3T3-L1 preadipocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-008-1046-4

Atorvastatin increases lipoprotein lipase expression in vitro and activity in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-008-1046-4

Effects of atorvastatin on the intracellular stability and secretion of apolipoprotein B in HepG2 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-008-1046-4

Lipoprotein heterogeneity and apolipoprotein B metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-008-1046-4

Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the cholesterol and recurrent events (CARE) trial. The Care Investiga

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-008-1046-4

Apolipoprotein B metabolism in homozygous familial hypercholesterolemia

21 January 2018

1 reference

12 December 2020

3-Hydroxy-3-methylglutaryl CoA reductase inhibitors reduce serum triglyceride levels through modulation of apolipoprotein C-III and lipoprotein lipase

1 reference

12 December 2020

New insight into the pathophysiology of lipid abnormalities in type 2 diabetes

1 reference

12 December 2020

Effects of NIDDM on very-low-density lipoprotein triglyceride and apolipoprotein B metabolism. Studies before and after sulfonylurea therapy

1 reference

12 December 2020

Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial

1 reference

12 December 2020

Differential regulation of apolipoprotein B secretion from HepG2 cells by two HMG-CoA reductase inhibitors, atorvastatin and simvastatin

1 reference

12 December 2020

Induction of LPL gene expression by sterols is mediated by a sterol regulatory element and is independent of the presence of multiple E boxes

1 reference

12 December 2020

Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction

1 reference

12 December 2020

Tracer-to-tracee ratio for analysis of stable isotope tracer data: link with radioactive kinetic formalism

1 reference

12 December 2020

Sensitive methods to study human apolipoprotein B metabolism using stable isotope-labeled amino acids

1 reference

12 December 2020

Effect of insulin therapy on metabolic fate of apolipoprotein B-containing lipoproteins in NIDDM.

1 reference

12 December 2020

Effect of rosuvastatin on hepatic production of apolipoprotein B-containing lipoproteins in an animal model of insulin resistance and metabolic dyslipidemia

1 reference

12 December 2020

Diabetes and cardiovascular risk factors: the Framingham study

1 reference

12 December 2020

Rosuvastatin reduces plasma lipids by inhibiting VLDL production and enhancing hepatobiliary lipid excretion in ApoE*3-leiden mice

1 reference

12 December 2020

Diabetic dyslipidaemia: insights for optimizing patient management

1 reference

12 December 2020

Direct determination of human and rabbit apolipoprotein B selectively precipitated with butanol-isopropyl ether

1 reference

12 December 2020

Diabetes and atherosclerosis: an epidemiologic view

1 reference

12 December 2020

Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S)

1 reference

12 December 2020

Isotope Ratio Mass Spectrometry, Compared with Conventional Mass Spectrometry in Kinetic Studies at Low and High Enrichment Levels: Application to Lipoprotein Kinetics

1 reference

12 December 2020

Blood volume measurement: a critical study prediction of normal values: controlled measurement of sequential changes: choice of a bedside method

1 reference

12 December 2020

Significant improvement of apolipoprotein B-containing lipoprotein metabolism by insulin treatment in patients with non-insulin-dependent diabetes mellitus

1 reference

12 December 2020

Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial

1 reference

12 December 2020

High-density lipoprotein apolipoprotein A-I kinetics in obese insulin resistant patients. An in vivo stable isotope study

1 reference

12 December 2020

Early kinetic abnormalities of apoB-containing lipoproteins in insulin-resistant women with abdominal obesity.

1 reference

12 December 2020

Complete deficiency of the low-density lipoprotein receptor is associated with increased apolipoprotein B-100 production.

1 reference

12 December 2020

Treatment with high-dose simvastatin reduces secretion of apolipoprotein B-lipoproteins in patients with diabetic dyslipidemia

1 reference

12 December 2020

Atorvastatin improves diabetic dyslipidemia and increases lipoprotein lipase activity in vivo

1 reference

12 December 2020

Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial).

1 reference

12 December 2020

Increased hepatic secretion of very-low-density lipoprotein apolipoprotein B-100 in obesity: a stable isotope study

1 reference

12 December 2020

Metabolic abnormalities of apolipoprotein B-containing lipoproteins in non-insulin-dependent diabetes: a stable isotope kinetic study.

1 reference

12 December 2020

Effects of rosuvastatin, atorvastatin, simvastatin, and pravastatin on atherogenic dyslipidemia in patients with characteristics of the metabolic syndrome

1 reference

12 December 2020

Heterogeneity of apolipoprotein B-100-containing lipoproteins: what we have learnt from kinetic studies.

1 reference

12 December 2020

Effect of atorvastatin on apolipoprotein B100 containing lipoprotein metabolism in type-2 diabetes

1 reference

12 December 2020

Comparison of rosuvastatin with atorvastatin, simvastatin and pravastatin in achieving cholesterol goals and improving plasma lipids in hypercholesterolaemic patients with or without the metabolic syndrome in the MERCURY I trial

1 reference

12 December 2020

Dose-dependent effect of rosuvastatin on apolipoprotein B-100 kinetics in the metabolic syndrome

1 reference

12 December 2020

PPARalpha and PPARgamma activators direct a distinct tissue-specific transcriptional response via a PPRE in the lipoprotein lipase gene

1 reference

12 December 2020

MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial

1 reference

12 December 2020

Hyperglycaemia is associated with all-cause and cardiovascular mortality in the Hoorn population: the Hoorn Study

1 reference

12 December 2020

Defective regulation of triglyceride metabolism by insulin in the liver in NIDDM

1 reference

12 December 2020

Diabetic dyslipidaemia: from basic research to clinical practice.

1 reference

12 December 2020

A minimal model using stable isotopes to study the metabolism of apolipoprotein B-containing lipoproteins in humans.

1 reference

12 December 2020

Homeostasis model assessment: insulin resistance and ?-cell function from fasting plasma glucose and insulin concentrations in man

1 reference

12 December 2020

Increased hepatic secretion of very-low-density lipoprotein apolipoprotein B-100 in NIDDM

1 reference

12 December 2020

10.1007/S00125-008-1046-4

Identifiers

DOI

1 reference

23 December 2017

PubMed ID

18535816

1 reference

23 December 2017